Our People
A closed loop for molecular design. Every cycle produces proprietary training data, making the next cycle smarter.
The platform's first output. A compact RNA-guided nuclease with 40 percent of its sequence rewritten from nature, active in human cells, with up to 3x the activity of existing compact editors.
bioRxiv, 2026
Cell Reports Methods, 2024
How the ACE design search ran on NVIDIA GPUs, where BioNeMo fits, and why working editors per GPU hour is the number we track.
Integrating frontier AI capabilities with the Acrobat platform to accelerate molecular design for rare disease.
Successful Phase I completion in the DARPA Rapid Inhibitor Discovery and Development pipeLine (RIDDL) program and advancement to expanded Phase II research.
Multi-year award supporting application of the Acrobat platform to protein engineering in neurodegeneration.
Joint program applying spatial transcriptomic profiling to disease-localized target identification in interstitial lung disease.
We're always looking for exceptional scientists and engineers to join our team. If teaching AI the language of biology excites you, we'd love to hear how you'd contribute.
Get in touch
